SCHEMBL1521722

SCHEMBL1521722

CNc1cc2c(cn1)CN(c1ccc(F)c(NC(=O)Nc3cc(C(F)(F)F)nn3-c3ccccc3)c1)C(=O)N2C

nearest known ligand 0.48

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
KCNJ6 P48051 3/20 0.48
KCNJ5 P48544 3/20 0.48
KCNJ3 P48549 3/20 0.48
BRAF P15056 7/20 0.45
MAPK14 Q16539 8/20 0.44
MAPK13 O15264 7/20 0.44
MAPK12 P53778 7/20 0.44
MAPK11 Q15759 7/20 0.44
RAF1 P04049 2/20 0.42
NTRK1 P04629 1/20 0.39
NTRK3 Q16288 1/20 0.39
NTRK2 Q16620 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1521965 0.94 MAPK14 (0.51) BRAFMAPK14MAPK13MAPK12MAPK11
SCHEMBL1521661 0.86 KCNJ6 (0.47) KCNJ6KCNJ5KCNJ3BRAFMAPK14
SCHEMBL1521555 0.85 MAPK14 (0.53) BRAFMAPK14MAPK13MAPK12MAPK11
SCHEMBL1521794 0.85 MAPK14 (0.44) BRAFMAPK14MAPK13MAPK12MAPK11
SCHEMBL1521734 0.81 MAPK14 (0.51) BRAFMAPK14MAPK13MAPK12MAPK11
SCHEMBL1521906 0.81 KCNJ6 (0.46) KCNJ6KCNJ5KCNJ3BRAFMAPK14
SCHEMBL1521917 0.80 KDR (0.40) BRAFMAPK14RAF1NTRK3
SCHEMBL1521814 0.79 MAPK14 (0.52) BRAFMAPK14MAPK13MAPK12MAPK11
SCHEMBL1521968 0.79 KCNJ6 (0.45) KCNJ6KCNJ5KCNJ3BRAFMAPK14
SCHEMBL1521638 0.79 BRAF (0.47) BRAFMAPK14MAPK11RAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases FLYNN DANIEL L 2011-05-19 US claimed
US-7897762-B2 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2011-03-01 US claimed
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2009-04-16 US claimed
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases FLYNN DANIEL L 2011-05-19 US disclosed
US-7897762-B2 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2011-03-01 US disclosed
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases BRAF, PRKDC, RAF1 KCNJ6 990/4885KCNJ5 1019/4885KCNJ3 1035/4885
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 KCNJ6 990/4885KCNJ5 1019/4885KCNJ3 1035/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.